113 related articles for article (PubMed ID: 22525722)
1. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Cassinelli G; Zuco V; Petrangolini G; De Cesare M; Tortoreto M; Lanzi C; Cominetti D; Zaffaroni N; Orlandi A; Passeri D; Meco D; Di Francesco AM; Riccardi R; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2012 Jul; 84(2):163-71. PubMed ID: 22525722
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
3. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
Pisano C; De Cesare M; Beretta GL; Zuco V; Pratesi G; Penco S; Vesci L; Foderà R; Ferrara FF; Guglielmi MB; Carminati P; Dallavalle S; Morini G; Merlini L; Orlandi A; Zunino F
Mol Cancer Ther; 2008 Jul; 7(7):2051-9. PubMed ID: 18645015
[TBL] [Abstract][Full Text] [Related]
4. Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Beretta GL; Zuco V; De Cesare M; Perego P; Zaffaroni N
Curr Med Chem; 2012; 19(21):3488-501. PubMed ID: 22680917
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
Meco D; Di Francesco AM; Cusano G; Bucci F; Pierri F; Patriarca V; Torella AR; Pisano C; Riccardi R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):811-22. PubMed ID: 23007316
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.
De Cesare M; Beretta GL; Tinelli S; Benedetti V; Pratesi G; Penco S; Dallavalle S; Merlini L; Pisano C; Carminati P; Zunino F
Biochem Pharmacol; 2007 Mar; 73(5):656-64. PubMed ID: 17169332
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Zuco V; Supino R; Favini E; Tortoreto M; Cincinelli R; Croce AC; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2010 Feb; 79(4):535-41. PubMed ID: 19765546
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
Vistica DT; Hollingshead M; Borgel SD; Kenney S; Stockwin LH; Raffeld M; Schrump DS; Burkett S; Stone G; Butcher DO; Shoemaker RH
J Pediatr Hematol Oncol; 2009 Aug; 31(8):561-70. PubMed ID: 19636271
[TBL] [Abstract][Full Text] [Related]
13. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
14. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
15. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.
Zhang H; Issekutz AC
Am J Pathol; 2002 Jun; 160(6):2219-30. PubMed ID: 12057924
[TBL] [Abstract][Full Text] [Related]
16. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini G; Pratesi G; De Cesare M; Supino R; Pisano C; Marcellini M; Giordano V; Laccabue D; Lanzi C; Zunino F
Mol Cancer Res; 2003 Oct; 1(12):863-70. PubMed ID: 14573787
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
